Publications by authors named "C Weil-Olivier"
AFTER-EFFECTS OF INVASIVE MENINGOCOCCAL DISEASES. Invasive meningococcal infections (IMI) still have a mortality rate of 11% in France. Recent nationwide studies have been able to quantify the long-term sequelae among survivors and highlight their diversity.
View Article and Find Full Text PDFA panel of 24 international experts met in July 2022 to discuss challenges associated with pertussis detection, monitoring, and vaccination in adults; conclusions from this meeting are presented. There has been a shift in the epidemiology of pertussis toward older children and adults. This shift has been attributed to the waning of infection- or vaccine-induced immunity, newer detection techniques causing detection bias, and possibly the replacement of whole-cell pertussis with acellular vaccines in high-income countries, which may lead to immunity waning more quickly.
View Article and Find Full Text PDFArticle Synopsis
- Invasive meningococcal disease (IMD) is often focused on younger populations, but it significantly impacts adults aged 60 and older, leading to increased morbidity and mortality rates.
- Routine immunization for children and adolescents has effectively reduced cases in these groups, but older adults remain largely unvaccinated, making up to 25% of current IMD cases in developed countries.
- Awareness and action are needed to address this issue, urging healthcare providers and policymakers to improve meningococcal vaccination access for older adults.
Article Synopsis
- Pertussis, also known as whooping cough, is infecting more older children and adults, which is causing problems for health care and people's quality of life.
- There is a plan to improve vaccination to protect everyone, but we don't have enough information about how effective adult vaccines are or how often adults actually get pertussis.
- To make better decisions about adult vaccinations, we need more data about how common pertussis is in adults, why some people skip vaccines, and how well the vaccines work over time.
New technologies for the prevention of infectious diseases are emerging to address unmet medical needs, in particular, the use of long-acting monoclonal antibodies (mAb) to prevent Respiratory Syncytial Virus (RSV) lower respiratory tract disease in infants during their first RSV season. The lack of precedent for mAbs for broad population protection creates challenges in the assessment of upcoming prophylactic long-acting mAbs for RSV, with associated consequences in legislative and registration categorization, as well as in recommendation, funding, and implementation pathways. We suggest that the legislative and regulatory categorization of preventative solutions should be decided by the effect of the product in terms of its impact on the population and health-care systems rather than by the technology used or its mechanism of action.
View Article and Find Full Text PDF